News

Vertex wins European approval for Alyftrek, bolstering cystic fibrosis stronghold
With its blockbuster Trikafta set to lose patent protection within the decade, Vertex is strengthening its cystic fibrosis ...
The Pharma Letter3d
EC greenlight for Vertex’ Alyftrek
Vertex Pharmaceuticals today announced that the European Commission has granted approval for Alyftrek ...
Stocktwits on MSN3d
Vertex Pharma’s New Cystic Fibrosis Drug Granted Approval By EU
Vertex Pharmaceuticals (VRTX) on Tuesday announced that the European Commission has granted approval for Alyftrek for the ...
Vertex Down Around 9% in Three Months: Should You Buy, Sell or Hold the Stock?
VRTX slips 9% in three months on slow new drug uptake and pipeline hiccups, but CF strength and 2025 growth offer a reason to ...